Patent Application
20240181458
The present disclosure relates to the field of live cell culture, the quantification of cell migration, and the metastatic potential of tumor cells.
Cancer is the second largest worldwide cause of death and poses the highest clinical, social, and economic burden among all human diseases. The majority of cancer deaths are caused by metastases, where the tumor cells have detached from the primary tumor and spread to distant organs.
Existing solutions to predict the outcome of breast tumors and the likelihood of metastasis have emerged in recent years. These include classical pathology (e.g., histopathology and MRI/PET scan), and biomarkers (e.g., the presence of receptors for estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2)). However, classical pathology only detects metastases in advanced stages and while biomarkers are used to classify breast cancer and provide information on whether hormonal treatment would be advantageous and prediction of recurrence, they do not directly determine metastatic potential. Significant efforts have been made to develop high-throughput molecular technologies to identify molecular markers such as gene signatures to guide decision-making processes (e.g., PAM50, MammaPrint). New biomarkers aim at discovering metastasis but are limited by detecting a single or a small set of genes or proteins, which provides only indirect indication of potential metastasis in specific subclasses of breast cancer. Moreover, interpretation and clinical translation of results from multiple genomic and proteomic analysis variables remain a significant challenge. Genetic testing can be expensive, time-consuming, and limited due to the biasing presence of normal cells and intratumoral heterogeneity. These methods have the drawback of only providing a snapshot of different factors and do not quantify the real-time migration and behavior of living cells.
Ideally, reliable diagnostics could help to distinguish invasive tumor cells and, subsequently, to define appropriate treatment strategies at an early stage. However, a method that can definitively and efficiently determine whether a primary tumor will metastasize does not exist today and the ability to tailor the patient's therapy is therefore limited. Further, the ability to predict and understand the mechanisms of metastasis would be of great value in the search for metastasis-limiting pharmaceutical therapies.
Chemotaxis studies have been crucial for the study of cell migration and tumor metastasis. One way to investigate and predict intratumoral cells' metastatic behavior is with the use of biomolecular gradients. Biomolecular gradients are established by a difference in the concentration of molecules in a biological system and are important for communication, adhesion, and morphology of cells. Different methods to provide chemical gradients have been established over the years. However, they are limited in their ability to produce precise and consistent enough controlled gradients for such studies.
Traditional methods of producing biomolecule gradients (gradient chambers, micropipette-generated, biological hydrogel) have been useful instrumentals in scientific research, however, they are limited in their ability to produce precise and quantitative results necessary for a diagnostic product. Biomolecule gradients constructed in free liquid solutions can behave inconsistently and diffuse over time and are highly susceptible to small vibrations, thermal imbalances, or evaporation. For biological hydrogel-based gradients, the use of cell-based biomolecule sources such as explants or transfected cell lines to form gradients leads to high variability in resultant gradients (Keenan TM, Folch A. Biomolecular gradients in cell culture systems. Lab Chip. 2008 Jan;8(1):34-57. doi: 10.1039/b711887b. Epub 2007 Dec 6. PMID: 18094760; PMCID: PMC3848882). These limitations mean that cells are not exposed to a constant, precise user-defined gradient and results are often not quantitative and not of adequate precision, both of which necessary for a diagnostic product.
Moreover, existing cell migration assays do not replicate the real-life tumor conditions and are therefore not an accurate representation of tumor cells in vivo. Further, they are not able to combine multiple factors and biomolecule gradients, a key competent in order to replicate in vivo cellular conditions.
In recent years microfluidic technology has been developed for chemotaxis and cell migration studies and a proposed way to overcome the above noted limitations. An example of this is US 2018 0 280 976, which relates to gradient-on-a-chip, which discloses a cell culture device and its applications of creating gradient of chemicals or gradient of cells to mimic the in vivo physiological conditions of homeostasis.
Some work has been done to apply the technology to determine metastatic potential of cells derived from cancer patients. Examples include US 2016 0 158 751 and US 2020 0 249 232 which discloses the use of an integrated microfluidic chip for analysis of cell motility and prediction and prognosis of patient survival, with or without a chemical gradient.
US 2018/0172694 A1 discloses sensor arrays for detecting biomolecules and methods of use. The plurality of sensor elements in the sensor arrays comprises, consists essentially of, or consists of a plurality of particles. Each particle is differentiated from each other by at least one physicochemical property such that each sensor element has a unique biomolecule corona signature when placed in contact with the same sample. The size of the particles in different sensor elements may thus differ to affect the binding selectivity. There is, however no variation in average inter-particle distance. A variation in the inter-particle distance may provide variation in the binding selectivity for a given sensor element.
US 2002/0028451 A1 discloses a detection apparatus for use in the detection of the presence of a selected pathogen in a sample. Such apparatus include: a substrate with a detection region on a surface thereof, the detection region having microstructures including grooves formed therein that will align liquid crystal material in contact therewith, the width and depth of the grooves being in the range of 10 μm or less; a blocking layer on the surface of the detection region of the substrate that does not disrupt the alignment of liquid crystal material in contact therewith, the blocking layer blocking nonspecific adsorption of pathogens to the surface; and a binding agent on the surface of the detection region of the substrate, the binding agent specifically binding the selected pathogen. The detection region may be coated with a continuous metallic layer, e.g., a silver or a gold film, applied by vacuum deposition.
WO 2008/021071 describes methods and compositions based on liquid crystal assays and other biophotonically based assays for detecting and quantifying the number of cells present on a test surface or within a test substrate and the proliferation, death, or movement of cells under control conditions and in response to chemotactic and other cytoactive (including compounds that are chemokinetic but not chemotactic and agents that inhibit cell migration) agents. In order to provide wells on the test surface that are isolated from each and not being in fluid communication with each other, particles may be deposited on the test surface in patterns to provide raised walls or partitions. In this manner, an analyte (e.g., a potential chemotactic agent) placed in a particular well remains substantially confined to that well. Further, patterning may allow the creation of microchannels through the device whereby an agent can exit such that e.g., diffusion gradients for testing whether a test compound is a chemotactic agent, i.e., whether the direction of movement of motile cells or organisms are affected by a diffusion gradient of a diffusible test compound.
However, these newer methods also have drawbacks. Disadvantages of microfluidics-based methods include their cost, complexity, and that the forces and pressures present could be disturbing or damaging to cells. These are still subject to inconsistency in gradient and conditions for the cells due to the fluidic nature of the apparatuses.
Thus, there exists a need for a more effective device and method for measuring tumor cell migration and determine the metastatic potential of tumors cells.
An object of the disclosure is to provide a method and device that can be used to measure migration capacity, i.e., the movement of a cell, and metastatic potential of tumor cells in vitro.
According to a first aspect of the disclosure, these and other objects are achieved, in full or at least in part, by a gradient-on-a-chip device for quantification of cell migration and metastatic potential of tumor cells. The device comprises:
The chip surface further has at least one guiding structure arranged to guide the tumor cells in the gradient direction. The guiding structure extends in the gradient direction and delineates a migration corridor comprising the nano gradient layer.
Nano gradients constitute a useful tool to induce cell migration. It was envisaged that surface-bound nano-gradient may overcome many of the issues in the field as they provide a precise and controllable continuous gradient. A preferred type of a precise and controllable continuous gradient is disclosed in WO 2012/025576.
The nano gradient layer, according to the invention, may be described as a dispersion of nanoparticles onto a chip surface in a gradient pattern, where the density of particles increases along one axis of the chip surface. The nano gradient layer may for example consist of nano-patterns of gold nanoparticles, onto which biomolecules of interest are attached. It is created to mimic tissue function at the molecular level, e.g., intra-tumoral spaces. The gradient layer may be utilized to influence and direct cell migration along the gradient direction of the nano gradient layer. It may also be utilized to screen for sensitive reactions and/or interactions between cells and biomolecules, thus determining the optimal composition of biomolecules responsible for a certain cellular response. The region on the gradient responsible for a reaction may then be recreated in a nano layer. A method for producing the nano gradient layer is described in WO 2012/025576.
However, the measurement of cell migration in a nano gradient layer can be problematic due to interactions between cells. Such cell-cell interactions occur when adjacent cells get in contact, and often causes the cells to change its migration path, possibly in a direction opposite the gradient direction of the nano gradient. The cell-cell interactions thus disturb the migration behavior of the cells. Furthermore, cell-cell interactions may complicate screening and analyzation of the interactions between cells and biomolecules.
The more cells present in a specified area, the greater risk that disturbing cell-cell interactions will occur when the cells starts to migrate. Measurements has shown that severe cell-cell interactions may disturb cell migration to such an extent that it is difficult, if not even possible, to retain accurate analyzation results of cells migration behavior. Cell-cell interaction may also cause disturbance when an optimal composition between cells and biomolecules is to be determined.
The inventors have solved this problem by a guiding structure arranged in the gradient direction. The guiding structure extending in the gradient direction is meant to be understood as the guiding structure extending substantially parallel with the gradient direction.
The function of the guiding structure is to delineate a migration corridor for the cells. Hereby, the migration corridor is delimited by the guiding structure. A migration corridor may be defined as the space between the guiding structure and the outer edge of the chip surface. A device having only one single guiding structure may thus contain two migration corridors, the two of them located on each side of the guiding structure. Further, also the space located between two adjacent and parallel guiding structures may define a migration corridor. According to an embodiment, the migration corridor is delineated by two adjacent and parallel guiding structures.
The migration corridor is adapted to guide the cells in the gradient direction along the nano gradient layer and to prevent cells from interacting with each other. Hereby, the area for each cell to migrate in is delimited. The device thus has the advantage that it eliminates disturbance from cell-cell interactions.
Moreover, the migratory behavior of tumor cells within a migration corridor may be more correctly and reliantly measured and recorded than without migration corridors, which enhances the capability of predicting cells' ability to spread and metastasize. A further advantage is that the time for measurement may be shortened when cell-cell interactions are avoided.
According to one embodiment, the nanogradient layer is a continuous nanogradient layer. This means the concentration of nanoparticles increases continously in the gradient direction.
According to at least one example embodiment, the guiding structure is a ridge extending out of the chip surface or a recession pointing into the chip surface. Such a ridge may be 1 to 100 μm high, such as 10 to 30 μm high. Further non-limiting examples of guiding structures are cuts, scores, notches, or incisions in the chip surface. These examples illustrate guiding structures that are contained in the chip surface. The depth of such guiding structures may be 1 to 100 μm, such as 10 to 30 μm. Alternatively, the chip surface may be modified with excess material to create a guiding structure in the form of a ridge or a wall. The guiding structure may contain the same material as the chip and/or a different material. Further, the width of the guiding structure may be at least 1 μm, such as 1 to 900 μm, or 5 to 500 μm. The width may be measured in the plane from which the guiding structure extends out of, or into, the chip surface.
According to at least one example embodiment, the guiding structure extends continuously along the chip surface. This is to be interpreted as the guiding structure extending continuously along the migration corridor. Hereby, the delineation of the migration corridor is continuous along the gradient direction of the chip surface.
In an embodiment, the guiding structure extends continuously along a portion of the chip surface. Alternatively, the guiding structure may extend discontinuously along the corridor. There may for example be breaks in the guiding structure along the gradient direction.
According to at least one example embodiment, the device further comprises a chip surface area void of nano gradient layer, and wherein the guiding structure is the boundary line between the migration corridor and the chip surface area void of nano gradient layer.
This is to be interpret as the migration corridor being delimited by a surface area void of nano gradient layer. An area void of nano gradient layer also means an area void of biomolecules. Such an area is not pleasant for the cells to migrate into, or uphold themselves in, as they prefer to interact with the biomolecules and thus follow the gradient direction.
According to at least one example embodiment, the migration corridor has a substantially constant width along its extension direction.
The migration corridor has thus equal width in both end points. By having a constant width along the extension direction, the cells are induced to travel linearly in the gradient direction.
According to at least one example embodiment, the migration corridor has a width in the range of 20 to 500 μm, and preferably 50 to 200 μm.
According to an embodiment, the migration corridor has a width in the range from 30 to 120 μm, more preferably 40 to 80 μm, and most preferably 50 to 60 μm.
Hereby, the width of the corridor matches a cell size of about 50 μm. By having a corridor width matching the size of the cell, linear cell migration may be induced. A corridor having the width of 50 to 60 μm, e.g., about 50 μm, is preferably used for the measurement of a single cell or a low number of cells, e.g., cells that have been loaded at different loading areas along the gradient direction. A wide corridor has the advantage that a plurality of cells may be present in the same corridor. Whereas one typically would like to minimize cell interactions, there may still be some types of experiments in which it would be of interest to have a plurality of cells present in the same corridor.
The corridor may be up to 20 mm long, such as 1 to 20 mm long. Typically, the corridor is about 5 mm long, such as 1 to 10 mm long, or 2 to 8 mm long. The corridor may have length:width ratio of 1000:1 to 2:1. According to an embodiment, the corridor has length:width ratio of 200:1 to 20:1
According to at least one example embodiment, the gradient-on-a-chip device comprises two or more migration corridors. Two or more migration corridors allow simultaneous measurement of the migration behavior of a plurality of cells. This is beneficial since it saves time for analyses. The more migration corridors that are present, the more cells may be measured simultaneously.
According to at least one example embodiment, the gradient-on-a-chip device comprises at least 50 migration corridors, at least 100 migration corridors, or at least 150 migration corridors. The number of migration corridors may be correlated to the size of the chip. A large chip has the benefit that more corridors may be present than on a small chip.
According to an embodiment, the device comprises two or more guiding structures.
According to an embodiment, the device comprises at least 25 guiding structures, preferably at least 50 guiding structures, and most preferably at least 100 guiding structures.
According to at least one example embodiment, the two or more migration corridors are of equal width.
This may be achieved by providing a single guiding structure provided in the center of the chip surface, the guiding structure delineating two separate migration corridors provided on each side of the guiding structure.
An advantage of having two or more migration corridors of equal width is the results of different cells can be compared. A further advantage may be that the manufacturing could be easier and cheaper.
Alternatively, the device comprises two or more migration corridors of different widths.
According to an embodiment, the biomolecule is an epidermal growth factor (EGF). Other non-limiting examples of biomolecules are Semaphorin-3E (Sema3E), Semaphorin-4D (Sema4D), Semaphorin-5a (Sema5a), C—C motif chemokine 27 (CCL27), C—C motif chemokine 38 (CCL38), C—C motif chemokine 48 (CCL48), C—C motif chemokine 58 (CCL58), C—C motif chemokine 12 (CCL12), C—C motif chemokine 199 (CCL199), C—C motif chemokine 21 (CCL21), C—C motif chemokine 22 (CCL22), C—C motif chemokine 25 (CCL25), C—X—C motif chemokine 5 (CXCL5), C—X—C motif chemokine 8 (CXCL8) (IL-8), C—X—C motif chemokine 9 (CXCL9), C—X—C motif chemokine 10 (CXCL10), C—X—C motif chemokine 12 (CXCL12), C—X—C motif chemokine 13 (CXCL13), C—X—C motif chemokine 14 (CXCL14), Interleukin-11 (IL-11), Fibroblast growth factor (FGF), Platelet-derived growth factor (PDGF), Placenta growth factor (PIGF), Hepatocyte growth factor (HGF), HB-EGF (Heparin-binding, EGF-like), Slit homolog 2 protein (Slit2), Vascular endothelial growth factor a (Vegf-a), Vascular endothelial growth factor b (Vegf-b), Vascular endothelial growth factor c (Vegf-c), Ephrin type-A receptor 2 (EphA2) (Eph-receptor), and Ephrin type-B receptor 4 (EphB4). In regard to mimicking the intratumoral environment, these biomolecules may be combined with ECM fibers such as fibronectin, collagen, elastin, or laminin.
In one embodiment, the chip surface between the nanoparticles, or at least a part of the chip surface between the nanoparticles, is coated by a coating agent, such as ECM fibers. An example of coating agent is fibronectin. Other examples of coating agents are laminin, collagen and elastin.
According to at least one example embodiment, the linker comprises the linker complex biotin/streptavidin. In such an embodiment, streptavidin may be attached to the particle, whereas biotin is attached to the biomolecule.
As already described, the device comprises a chip with a chip surface. A gradient of nanoparticles is provided on the chip surface. The particles may have a diameter in the range 1 to 100 nanometers (nm), such as in the range 3 to 30 nanometers (nm). Exemplary particles have a diameter of about 10 nanometers (nm). Other exemplary particles have a diameter of about 5 nanometers (nm) or about 20 nanometers (nm). Further, the average center-to-center distance between the nanoparticles may be 10 to 60 nm, such as 15 to 50 nm, in one end of the gradient and 100 to 150 nm in the other end of the gradient. The center-to-center distance between the nanoparticles is longer than the particle diameter, such as at least 10% longer than the particle diameter. According to an embodiment, at least 95% of the particles have a diameter in the stated range. According to an embodiment, at least 95%, such as at least 97.5%, of the particles have a diameter in the range 3 to 25 nm.
In one embodiment, the nanoparticles are gold particles. The gold particles may be coated with thiolated streptavidin. Further, the biomolecules may be biotinylated and attached to the nanoparticles through biotin/streptavidin interaction. The gold particles may have a diameter of 3 to 25 nm, such 5 to 20 nm. Exemplary gold particles may have a diameter of about 5±1, 10±1.5, or 20±4 nm.
However, any such known principle for facilitating binding and interaction between nanoparticles and a biomolecule may be used since the biotin/streptavidin interaction is only an interaction according to one embodiment. For instance, such interaction may be formed using an ion-exchange/interaction, hydrophobic interactions and dative binding, covalent binding of thiols, carbo di-imide chemistry, bi-functional linkers (such as EDC/NHS chemistry) or click chemistry.
According to at least one example embodiment, device further comprises two or more migration corridors provided on top of each other. This may be achieved by two chips, each with a nano gradient layer, provided on top of each other.
According to a second aspect of the disclosure, a method for quantification of cell migration and metastatic potential of tumor cells is provided. The method comprises the steps of:
Measuring and/or recording means that the position of the tumor cell on the chip surface is determined at various points in time. By this, the migration behavior of the cells may be documented. Non-limiting examples of features that may be determined are migration velocity, migration distance, migration motility and migration direction. Based on such features, cell migration may be quantified and in turn, the metastatic potential of tumor cells.
The method according to the inventive concept has the advantage that it may generate results within hours, therefore saving time and costs associated with diagnosis. The added information about the nature of the tumor behavior and risk allows for better targeted and earlier treatment than otherwise possible.
With this method it may be possible to screen and follow the migration behavior of tumor cells while elucidating the disturbance from cell-cell interactions. The method makes it possible to better analyze the interactions between the cells and the biomolecules, e.g., to analyze the impact the biomolecule provides to the cell migration. Furthermore, the method makes it possible to evaluate different biomolecules and evaluate pros and cons for different types of molecules in order to find out best possible alternative to predict metastasis potential of tumor cells.
The tumor cell may be applied within a migration corridor. The tumor cell may for example be applied in the beginning of the migration corridor, i.e., an end of the corridor. Alternatively, the cell may be applied just outside a migration corridor.
According to an embodiment, the tumor cell is applied in an end of the migration corridor having the lowest nanoparticle concentration. Hereby, the cell is induced to migrate from an area with lower concentration of biomolecules to an area of higher concentration of biomolecules.
Alternatively, the cell is applied in an area of intermediate nanoparticle concentration, i.e., an area located in between the highest concentration of nanoparticles and the lowest concentration of nanoparticles. By applying the cell applied in an area of intermediate nanoparticle concentration, both an attractive as well as a repellant effect of chemotactic biomolecules may be studied.
According to at least one example embodiment, the measuring and recording is performed by imaging and/or isotope analysis.
According to at least one example embodiment, the tumor cell is a breast cancer cell, a melanoma cancer cell, a prostate cancer cell, a colorectal cancer cell, or a lung cancer cell.
According to a third aspect of the disclosure, the use of the gradient-on-a-chip device according to the first aspect for quantification of cell migration and metastatic potential of tumor cells is provided.
According to at least one example embodiment, the tumor cell is a breast cancer cell, a melanoma cancer cell, a prostate cancer cell, a colorectal cancer cell, or a lung cancer cell. Non-limiting examples of features that may be measured and recorded are migration velocity, migration distance, migration motility, and migration direction.
The present invention provides a gradient with multiple biomolecules and features that mimic conditions in vivo. This unlocks the ability to study tumor cells in real-time, with tumor microenvironment features and use this information to determine the metastatic potential of cell populations.
The device and the method can be used in a laboratory as a part of a diagnostic product on live patient tumor cells derived from a biopsy test at multiple points during a patient's cancer diagnostic, treatment, and monitoring.
Gradient is in this context meant concentration or density gradient, defined as the difference in the concentration or density of a substance between two areas.
A nano gradient layer is a surface covered with nanoparticles of which the distance between adjacent nanoparticles increase, or decrease, in a given direction from a given reference point.
The term nanoparticle is in this context meant particles of size between 1 and 100 nanometers (nm) in diameter.
The term nano gradient layer is surface covered with nanoparticles of which the distance between adjacent nanoparticles increase, or decrease, in a given direction from a given reference point.
The term continuous nano gradient layer is surface covered with nanoparticles of which the distance between adjacent nanoparticles increase, or decrease, continuously in a given direction from a given reference point.
The term gradient direction is in this context interpreted as the direction in which the distance between adjacent nanoparticles decrease or increase from a given reference point.
Generally, all terms used in the claims are to be interpreted according to their ordinary meaning in the technical field, unless explicitly defined otherwise herein. All references to “a/an/the [element, device, component, means, step, etc.]” are to be interpreted openly as referring to at least one instance of the element, device, component, means, step, etc., unless explicitly stated otherwise. The steps of any method disclosed herein do not have to be performed in the exact order disclosed, unless explicitly stated.
The disclosure will be described in more detail with reference to the appended schematic drawings, which show an example of a presently preferred embodiment of the disclosure.
The present disclosure will now be described more fully hereinafter with reference to the accompanying drawings, in which currently preferred embodiments of the disclosure are shown. The present disclosure may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided for thoroughness and completeness, and to fully convey the scope of the disclosure to the skilled addressee. Like reference characters refer to like elements throughout.
The nano gradient layer extends over the entire chip surface 11 and comprises nanoparticles 50 provided in a gradient pattern. The nanoparticles 50 are for example, gold nanoparticles 50. An advantage with gold particles is that gold is inert and easy to link biomolecules to.
The nanoparticles 50 have a biomolecule applied to them. The biomolecule is attached to the nanoparticles 50 via a linker conjugated to the nanoparticles 50. The function of the linker is to enhance the adherence of the biomolecule to the nanoparticles 50, and is preferably located such that the cells easily can attract to them, such that the cells are affected by the linker. The linker is for example biotin.
The nano gradient layer has a gradient direction in an axis of the X-Y plane of the chip surface 11, for example in the X-axis. The chip surface 11 which the nano gradient is provided on, comprises at least one guiding structure 20 arranged in the gradient direction. The device 1 in
In order to measure cell migration, metastatic cells are provided within a migration corridor 30 of the device 1. The device 1 in
The cells are preferably repeatedly measured and recorded mapped in order to quantify migration, e.g., rate, distance, direction and/or motility. Mapping may be by, e.g., imaging and/or by isotope analysis.
In the following example, cell migration was measured and compared on a gradient-on-chip device provided with migration corridors to the results obtained from a gradient-on-chip device without migration corridors. Using a gradient layer of nanoparticles (10 nm in diameter) (Cline NanoGradient, Cline Scientific, Sweden), conjugation of the biomolecules EGF to the nanoparticles and fibronectin in between the nanoparticles was conducted, scores of 1 to 2 μm depth and 1 to 5 μm width were generated on the left half of the nano-gradient surfaces in the same orientation as the biomolecule gradient direction using a diamond cuter under clean and humid condition to provide migration corridors. After the generation of the corridors, the nano-gradient surfaces were mounted in a Sarstedt 6 well plate, held in place using special clamps, and kept in PBS buffer solution supplemented with penicillin/streptomycin (1%, HyClone) until use. BT-549 (triple-negative breast cancer cells, ATCC) were cultured to 60% confluency in culture medium (RPMI medium supplemented with insulin (1 μg/mL, GIBCO™), Sodium-pyruvate (1 mM), non-essential amino acids (1%, HyClone), L-glutamine (2 mM, HyClone) and 10% fetal bovine serum (HyClone) until 24 hours prior to the experiment start point where the culture medium was replaced with the starvation medium (RPMI medium supplemented with Sodium-pyruvate, non-essential amino acids, L-glutamine and 1% fetal bovine serum). On the experiment day, cells were detached from the culture flask using TrypLE Express (GIBCO™) according to the manufacturer's protocol and seeded on the nano-gradient surfaces at a concentration of 4000 cells/cm2 in the starvation medium. The 6 well plates containing the nano-gradient surfaces and cells were placed in an incubator (37 C, 90% Rh, 5% CO2) for 4 hours to allow cells to attach to the nano-gradient surfaces prior to real-time holographic imaging using a HoloMonitor® M4 (phi, Sweden) placed in the incubator (37 C, 90% Rh, 5% CO2). The segmentation and tracking analysis and data extraction were performed using the Hstudio™ software (PHI AB, Sweden).
However, it was observed at around 4 hours that this effect on migration directness diminishes. Given the scores also limit the available space for cells on the nano-surface, over time, this resulted in increased cell-cell or cell-edge interactions when more than one cell is present. In addition, longer-term study of the cells introduces additional confounding factors such as cell division and change in motility speed which increases the probability of cell-cell interactions over time. Therefore, it is essential to design and induce scores (guiding structures) of proper dimensions to minimize cell-cell interaction over time.
The skilled person realizes that a number of modifications of the embodiments described herein are possible without departing from the scope of the disclosure, which is defined in the appended claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 21161887.1 | Mar 2021 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2022/056177 | 3/10/2022 | WO |
